TY - JOUR
T1 - JAK2 V617F mutation, multiple hematologic and non-hematologic processes
T2 - An association?
AU - Liu, Kenneth G.
AU - Verma, Amit
AU - Derman, Olga
AU - Kornblum, Noah
AU - Janakiram, Murali
AU - Braunschweig, Ira
AU - Battini, Ramakrishna
N1 - Publisher Copyright:
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
PY - 2016
Y1 - 2016
N2 - Background: Population studies showed that patients with JAK2 V617F mutation had increased mortality, and increased risk of any cancer, hematologic cancer, and myeloproliferative disease. Case presentation: A 68-year-old Asian male with JAK2 V617F mutation developed four different hematologic and non-hematologic neoplastic processes. In 2009, he was diagnosed with stage IA lung adenocarcinoma and also noted to have worsening leukocytosis and thrombocytosis with peak platelet count of 1,054,000/mL). Bone marrow biopsy was consistent with myeloproliferative neoplasm. His monocyte percentage increased in 2011 and met criteria for chronic myelomonocytic leukemia. In 2013, he was admitted for proximal small bowel obstruction, with biopsy confirming stage IE diffuse large B-cell lymphoma. In 2014, a bone marrow biopsy performed for worsening leukocytosis was consistent with acute myeloid leukemia with monocytic differentiation. Conclusion: This is a rare case depicting the association of JAK2 V617F mutation with myeloproliferative, lymphoproliferative and solid neoplasms.
AB - Background: Population studies showed that patients with JAK2 V617F mutation had increased mortality, and increased risk of any cancer, hematologic cancer, and myeloproliferative disease. Case presentation: A 68-year-old Asian male with JAK2 V617F mutation developed four different hematologic and non-hematologic neoplastic processes. In 2009, he was diagnosed with stage IA lung adenocarcinoma and also noted to have worsening leukocytosis and thrombocytosis with peak platelet count of 1,054,000/mL). Bone marrow biopsy was consistent with myeloproliferative neoplasm. His monocyte percentage increased in 2011 and met criteria for chronic myelomonocytic leukemia. In 2013, he was admitted for proximal small bowel obstruction, with biopsy confirming stage IE diffuse large B-cell lymphoma. In 2014, a bone marrow biopsy performed for worsening leukocytosis was consistent with acute myeloid leukemia with monocytic differentiation. Conclusion: This is a rare case depicting the association of JAK2 V617F mutation with myeloproliferative, lymphoproliferative and solid neoplasms.
KW - Acute myeloid leukemia
KW - Case report
KW - Chronic myelomonocytic leukemia
KW - Diffuse large B-cell lymphoma
KW - JAK2 V617F
KW - Lung adenocarcinoma
KW - Myeloproliferative neoplasm
UR - http://www.scopus.com/inward/record.url?scp=85028191329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028191329&partnerID=8YFLogxK
U2 - 10.1186/s40364-016-0073-4
DO - 10.1186/s40364-016-0073-4
M3 - Article
AN - SCOPUS:85028191329
SN - 2050-7771
VL - 4
JO - Biomarker Research
JF - Biomarker Research
IS - 1
M1 - 19
ER -
